Literature DB >> 22977370

Cloning of a Recombinant Plasmid Encoding Thiol-Specific Antioxidant Antigen (TSA) Gene of Leishmania majorand Expression in the Chinese Hamster Ovary Cell Line.

Ghaffarifar Fatemeh1, Tabatabaie Fatemeh, Sharifi Zohreh, Dalimiasl Abdolhosein, Hassan Mohammad Zahir, Mahdavi Mehdi.   

Abstract

BACKGROUND: TSA (thiol-specific antioxidant antigen) is the immune-dominant antigen of Leishmania major and is considered to be the most promising candidate molecule for a recombinant or DNA vaccine against leishmaniasis. The aim of the present work was to express a plasmid containing the TSA gene in eukaryotic cells.
METHODS: Genomic DNA was extracted, and the TSA gene was amplified by polymerase chain reaction (PCR). The PCR product was cloned into the pTZ57R/T vector, followed by subcloning into the eukaryotic expression vector pcDNA3 (EcoRI and HindIII sites). The recombinant plasmid was characterised by restriction digest and PCR. Eukaryotic Chinese hamster ovary cells were transfected with the plasmid containing the TSA gene. Expression of the L. major TSA gene was confirmed by sodium dodecyl sulphate-polyacrylamide gel electrophoresis and Western blotting.
RESULTS: The plasmid containing the TSA gene was successfully expressed, as demonstrated by a band of 22.1 kDa on Western blots.
CONCLUSION: The plasmid containing the TSA gene can be expressed in a eukaryotic cell line. Thus, the recombinant plasmid may potentially be used as a DNA vaccine in animal models.

Entities:  

Keywords:  CHO cells; Leishmania major; gene expression; genetics; plasmid; recombinant DNA

Year:  2012        PMID: 22977370      PMCID: PMC3436491     

Source DB:  PubMed          Journal:  Malays J Med Sci        ISSN: 1394-195X


  19 in total

1.  Genomic organization and gene expression in a chromosomal region of Leishmania major.

Authors:  Séverine Monnerat; Santiago Martinez-Calvillo; Elizabeth Worthey; Peter J Myler; Kenneth D Stuart; Nicolas Fasel
Journal:  Mol Biochem Parasitol       Date:  2004-04       Impact factor: 1.759

2.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

Review 3.  Leishmaniasis: current status of vaccine development.

Authors:  E Handman
Journal:  Clin Microbiol Rev       Date:  2001-04       Impact factor: 26.132

4.  Identification of Leishmania major cysteine proteinases as targets of the immune response in humans.

Authors:  S Rafati; A H Salmanian; K Hashemi; C Schaff; S Belli; N Fasel
Journal:  Mol Biochem Parasitol       Date:  2001-03       Impact factor: 1.759

5.  Vaccination with plasmid DNA encoding TSA/LmSTI1 leishmanial fusion proteins confers protection against Leishmania major infection in susceptible BALB/c mice.

Authors:  A Campos-Neto; J R Webb; K Greeson; R N Coler; Y A W Skeiky; S G Reed
Journal:  Infect Immun       Date:  2002-06       Impact factor: 3.441

6.  Protection against cutaneous leishmaniasis induced by recombinant antigens in murine and nonhuman primate models of the human disease.

Authors:  A Campos-Neto; R Porrozzi; K Greeson; R N Coler; J R Webb; Y A Seiky; S G Reed; G Grimaldi
Journal:  Infect Immun       Date:  2001-06       Impact factor: 3.441

Review 7.  Vaccines in leishmaniasis: advances in the last five years.

Authors:  Cláudia Brodskyn; Camila I de Oliveira; Aldina Barral; Manoel Barral-Netto
Journal:  Expert Rev Vaccines       Date:  2003-10       Impact factor: 5.217

8.  A comparative evaluation of different DNA vaccine candidates against experimental murine leishmaniasis due to L. major.

Authors:  Sami Ben Hadj Ahmed; Chokri Bahloul; Cyrine Robbana; Souhir Askri; Koussay Dellagi
Journal:  Vaccine       Date:  2004-04-16       Impact factor: 3.641

9.  Human and murine immune responses to a novel Leishmania major recombinant protein encoded by members of a multicopy gene family.

Authors:  J R Webb; A Campos-Neto; P J Ovendale; T I Martin; E J Stromberg; R Badaro; S G Reed
Journal:  Infect Immun       Date:  1998-07       Impact factor: 3.441

10.  DNA vaccines: designing strategies against parasitic infections.

Authors:  Catherine Ivory; Kris Chadee
Journal:  Genet Vaccines Ther       Date:  2004-12-03
View more
  3 in total

1.  Immune responses in DNA vaccine formulated with PMMA following immunization and after challenge with Leishmania major.

Authors:  Somayeh Zarrati; Mehdi Mahdavi; Fatemeh Tabatabaie
Journal:  J Parasit Dis       Date:  2014-08-31

2.  Th1 Platform Immune Responses Against Leishmania major Induced by Thiol-Specific Antioxidant-Based DNA Vaccines.

Authors:  Fatemeh Tabatabaie; Mehdi Mahdavi; Sobhan Faezi; Abdolhossein Dalimi; Zohreh Sharifi; Lame Akhlaghi; Fatemeh Ghaffarifar
Journal:  Jundishapur J Microbiol       Date:  2014-02-01       Impact factor: 0.747

3.  Induction of Immune Responses by DNA Vaccines Formulated with Dendrimer and Poly (Methyl Methacrylate) (PMMA) Nano-Adjuvants in BALB/c Mice Infected with Leishmania major.

Authors:  Fatemeh Tabatabaie; Nasim Samarghandi; Somayeh Zarrati; Fatemeh Maleki; Mehdi Shafiee Ardestani; Taher Elmi; Sayed Hussain Mosawi
Journal:  Open Access Maced J Med Sci       Date:  2018-01-27
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.